The bill amends the Human Services Code of Pennsylvania to introduce a subscription model for GLP-1 agonists, which are medications used to treat obesity. It mandates that the Department of Human Services seek a waiver from the Centers for Medicare and Medicaid Services to establish value-based arrangements with drug manufacturers through supplemental rebate agreements. These agreements would allow the Commonwealth to pay a predetermined amount for treatments up to a specified cap, after which the treatments would be provided at no cost to the Commonwealth.

Additionally, the bill outlines definitions for key terms related to the subscription model, including "GLP-1 agonist" and "supplemental rebate agreement." The implementation of this section is contingent upon federal approval, and the department is tasked with promulgating regulations to facilitate the model. The act is set to take effect 60 days after its passage.

Statutes/Laws affected:
Printer's No. 1731 (May 15, 2025): P.L.31, No.21